Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300

Benzinga Newsdesk www.benzinga.com Positive 72.5%

Neg 0% Neu 0% Pos 72.5%

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.